Nivatrotamab is a humanized bispecific antibody targeting GD2 on tumor cells and CD3 on T cells to enhance immune activation. It is being developed for the treatment of metastatic small cell lung cancer (SCLC) by recruiting T cells to attack tumors. M. W 200.96 kDa